摘要
前列腺癌(PCa)是全球男性癌症相关死亡的第二大原因。中国近年来PCa发病率显著升高。雄激素剥夺疗法(ADT)一直是晚期和转移性PCa的基础治疗方法。治疗初期疗效显著,但接受ADT的患者在后期会发生耐药,进而发展为去势抵抗性前列腺癌(CRPC)。获得ADT抗性的分子机制仍然不完全清楚,除了与雄激素受体(AR)相关的通路在CRPC发展的过程中起到重要作用外,更多的非AR相关的通路也被证明可以推动CRPC的发生发展。本文综述了PCa去势抵抗性获得的分子机制,有望为今后前列腺癌耐药机制的研究提供参考。
Prostate cancer(PCa)is the second leading cause of cancer-related deaths in men worldwide.In China,the incidence rate of prostate cancer has increased significantly.Androgen deprivation therapy(ADT)has always been the fundamental treatment method for advanced and metastatic prostate cancer.The initial efficacy of treatment is significant,but patients receiving ADT treatment may develop drug resistance in the later stages of treatment and develop castrated resistant prostate cancer(CRPC).However,the molecular mechanism by which ADT resistance is obtained is still not fully understood.In addition to the important role of androgen receptor-related signaling pathways in CRPC,an increasing number of non-AR pathways have also been shown to promote the occurrence and development of CRPC.This article reviews the molecular mechanism of PCa castration resistance,which is expected to provide a reference for future research on the mechanisms of drug resistance in prostate cancer.
作者
何静
郭燕
张晖
仓顺东
HE Jing;GUO Yan;ZHANG Hui;CANG Shundong(Zhengzhou University People’s Hospital,Zhengzhou 450003,China;Oncology Center,Henan Provincial People’s Hospital,Zhengzhou 450003,China;Henan University People’s Hospital,Zhengzhou 450003,China)
出处
《河南医学研究》
2026年第4期755-759,共5页
Henan Medical Research
基金
国家自然科学基金(82372896)。
关键词
前列腺癌
去势抵抗性前列腺癌
雄激素受体
prostate cancer
castrated resistant prostate cancer
androgen receptor
